Lung cancer treatment has changed drastically in recent years, and along with it the role of the pathologist. We spoke to Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, UK, about this at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland. Prof. Kerr highlights the increasing number of biomarkers, and the changing complexities and variety of pathology practice as a result.